Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LEAP THERAPEUTICS, INC.

(LPTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
3.41(c) 3.25(c) 3.39(c) 3.57(c) 3.57 Last
20 132 569 24 234 589 7 523 892 13 213 760 8 404 276 Volume
+23.10% -4.69% +4.31% +5.31% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2,93 M - -
Net income 2021 -39,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,40x
Yield 2021 -
Sales 2022 0,38 M - -
Net income 2022 -50,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,55x
Yield 2022 -
Capitalization 312 M 312 M -
Capi. / Sales 2021 106x
Capi. / Sales 2022 831x
Nbr of Employees 30
Free-Float 73,2%
More Financials
Company
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related... 
More about the company
Ratings of Leap Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about LEAP THERAPEUTICS, INC.
09/24LEAP THERAPEUTICS : Raises $104 Million After Completing Securities Offering; Stock Rises
MT
09/24LEAP THERAPEUTICS : Announces Closing of Public Offering of Common Stock and Pre-Funded Wa..
PU
09/24LEAP THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/24LEAP THERAPEUTICS : Announces Closing of Public Offering of Common Stock and Pre-Funded Wa..
PR
09/22AFTER HOURS WATCH LIST SCORECARD : Sfix, fdx, lptx,
MT
09/22LEAP THERAPEUTICS : Prices $90 Million Offering of Common Shares, Pre-Funded Warrants
MT
09/22LEAP THERAPEUTICS : Announces Pricing of $90 million of Common Stock and Pre-Funded Warran..
PU
09/22LEAP THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financ..
AQ
09/22LEAP THERAPEUTICS : Announces Pricing of $90 million of Common Stock and Pre-Funded Warran..
PR
09/21MT NEWSWIRES AFTER HOURS WATCH LIST : Sfix, fdx, lptx
MT
09/21LEAP THERAPEUTICS : Starts Offering Common Stock, Pre-Funded Warrants
MT
09/21LEAP THERAPEUTICS : Announces Proposed Public Offering of Common Stock and Pre-Funded Warr..
PU
09/21LEAP THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/21LEAP THERAPEUTICS : Announces Proposed Public Offering of Common Stock and Pre-Funded Warr..
PR
09/16US Stocks Mostly Lower Thursday After Surprise Retail Sales Gain, Rise in Jobless Claim..
MT
More news
News in other languages on LEAP THERAPEUTICS, INC.
09/24Leap Therapeutics lève 104 millions de dollars après avoir réalisé une offre de titres ..
09/22Leap Therapeutics propose un placement de 90 millions de dollars en actions ordinaires ..
09/21Leap Therapeutics commence à proposer des actions ordinaires et des bons de souscriptio..
09/16Les actions américaines en baisse jeudi après une hausse surprise des ventes au détail ..
09/16Les actions américaines terminent en grande partie en baisse, les investisseurs évaluan..
More news
Analyst Recommendations on LEAP THERAPEUTICS, INC.
More recommendations
Chart LEAP THERAPEUTICS, INC.
Duration : Period :
Leap Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEAP THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,57 $
Average target price 4,50 $
Spread / Average Target 26,1%
EPS Revisions
Managers and Directors
Doug E. Onsi President, CEO, CFO, Secretary & Treasurer
Chris K. Mirabelli Chairman
Cynthia Sirard Chief Medical Officer
Michael Haas Head-Research
Augustine J. Lawlor Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
LEAP THERAPEUTICS, INC.58.67%312
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.31%47 634